RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE
Clinical trials for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE explained in plain language.
Never miss a new study
Get alerted when new RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE trials appear
Sign up with your email to follow new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail ViPOR targets tough lymphomas in phase II trial
Disease control Recruiting nowThis phase II trial is testing a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive B-cell lymphomas that have come back or not responded to treatment. The study aims to see how many patien…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug tegavivint takes on tough lymphoma in early trial
Disease control Recruiting nowThis early-phase trial is testing a drug called tegavivint in about 18 people with large B-cell lymphoma that has come back or not responded to standard treatments. The drug works by blocking certain enzymes that help cancer cells grow. The main goals are to find a safe dose and …
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE
Phase: PHASE1 • Sponsor: Lapo Alinari • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo may help more lymphoma patients reach potentially curative CAR-T
Disease control Recruiting nowThis study tests whether giving two drugs, golcadomide and rituximab, before CAR-T cell therapy can help control aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The goal is to keep the disease in check so more patients can qualify for…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC